Waldencast plc
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Felipe Dutra
- Full Time Employees
- 367
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Address
- 81 Fulham Road London NY United Kingdom SW3 6RD
- IPO Date
- May 12, 2021
- CIK
- 0001840199
- Website
- waldencast.com
- Similar Companies
- Business
- Waldencast plc Waldencast plc operates as a global multi-brand beauty and wellness platform focused on acquiring, accelerating, and scaling conscious, purpose-driven brands in the skincare, cosmetics, and aesthetics sectors; its core portfolio includes Obagi Medical, offering clinically-backed skincare solutions for anti-aging, hyperpigmentation, acne, fine lines, and wrinkles, as well as in-office injectable hyaluronic acid gels such as Saypha ChIQ and MagIQ lines; Milk Makeup, providing vegan, cruelty-free cosmetics including foundations, concealers, liners, eyeshadows, lip colors, blush, bronzer, and setting sprays targeted at Gen Z and millennial consumers emphasizing self-expression and inclusivity; K18, delivering biotech-based professional hair repair treatments reversing damage from chemical, heat, and mechanical styling for salons and stylists; and Nudestix, featuring minimalist multi-functional makeup sticks for natural looks. The company serves professional markets including dermatologists, plastic surgeons, medical spas, and hair stylists, alongside direct-to-consumer channels via e-commerce platforms like www.MilkMakeup.com, retailers such as Sephora and Ulta Beauty, distributors, physicians, and third-party logistics providers; it operates across the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand from its headquarters in White Plains, New York, with additional offices in London. Founded in 2021 by Michel Brousset and Felipe Dutra, Waldencast plc went public via a SPAC merger on NASDAQ, raising $345 million initially, followed by the 2022 acquisitions of Obagi Skincare and Milk Makeup to expand its portfolio; recent developments include the July 2025 acquisition of Novaestiq Corp. and U.S. rights to the Saypha hyaluronic acid injectables to bolster Obagi Medical's aesthetics offerings and target the $2 billion U.S. dermal filler market, alongside new product launches such as Obagi Nu-Cil BioStim Scalp Serum, FDA approval for Obagi saypha MagIQ Injectable, balance sheet strengthening via a Japan trademark sale and credit facility refinancing, and reported Q2 2025 results reflecting operational progress with adjusted EBITDA margins expanding to 16.3% of net revenue.
Company News
Waldencast plc Files Form 15 to Deregister its Securities and Suspend its SEC Reporting Obligations under the Exchange Act
Waldencast plc Announces First Half 2026 Financial Results
Waldencast plc Files Form 25 to Voluntary Delist from Nasdaq and Deregister its Securities under the Exchange Act
Waldencast plc Announces Intention to Voluntarily Delist from Nasdaq and Deregister its Securities under the Exchange Act
Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
Waldencast Announces Sale of Obagi Medical to Bridgepoint
Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience
Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*
Waldencast announces conclusion of SEC investigation
Waldencast PLC (NASDAQ:WALD) Short Interest Up 61.6% in March
Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin's Age and Restore Visible Youthfulness
Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™
Brokerages Set Waldencast PLC (NASDAQ:WALD) Price Target at $4.42
Waldencast Reports Q4 2025 and FY 2025 Financial Results
Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date
Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Obagi Medical and It's a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™